A new blood test for Alzheimer’s detects active tau pathology with >95% accuracy with no need for a brain scan or spinal tap. Could this breakthrough reshape clinical trials and accelerate the pipeline for tau-directed therapies? hubs.la/Q03Lj4F40 #DrugDev #Neuroscience

Scientific credibility is more than expertise in the lab. When your leaders share insights, it builds trust, attracts talent, and positions your company as a thought leader. Read the full article to learn how: hubs.la/Q03Lj6yN0 #PharmaMarketing #B2BMarketing

GLP-1 drugs are revolutionizing diabetes and obesity care, and emerging research hints they may also influence cancer risk. Could managing weight and insulin resistance reduce certain cancers? Read the article to find out more: hubs.la/Q03Lj6zw0 #GLP1 #Oncology

The FDA’s August draft guidance on oncology radiopharmaceuticals changes dosing assumptions due to cumulative, delayed effects. Early discussions, long-term safety, and personalized dosimetry are key. Learn how to navigate these changes: hubs.la/Q03LjkTr0 #LifeSci #Oncology

Amid calls to tighten DTC pharma ads, 67% of patients with chronic diseases say they took action after seeing one. Many found ads helpful, but want more realism and support. Read the article to explore what patients say works and what doesn’t: hubs.ly/Q03Ljl-y0 #Pharma #DTC

In life sciences, expertise isn’t enough; visibility matters. We recommend using targeted keywords, on-page SEO, and relevant content to reach the right audience. Learn more about how strategic SEO can ensure your research makes an impact: hubs.ly/Q03Ljm6T0 #LifeSci #SEO

The FDA has issued draft guidance to support non-opioid pain drug development, aiming to expand treatment options and clarify trial expectations. Read the full article to see how this could shape future analgesic innovation: hubs.ly/Q03Ljlmf0 #LifeSci #DrugDev

Booking a FDA meeting can be tricky due to bureaucracy, bandwidth, and regulatory nuance. That's why our regulatory experts have developed a calculator to provide a clearer understanding of the steps and timeline. Give it a try here: hubs.la/Q03LjkfC0 #Compliance #FDA

Changes to CDC leadership and vaccine policy under RFK Jr. are drawing scrutiny from lawmakers and medical groups, with concerns over ACIP’s credibility and guidance. Learn what’s shifting and how stakeholders are responding: hubs.la/Q03Ljlt20 #PharmaNews #HealthPolicy

When drugs get FDA approval despite failing trials, patients gain faster access, but at what cost? Rare disease therapies highlight the tension between urgency and evidence, raising questions about safety, cost, post-market oversight, and outcomes hubs.la/Q03VND3-0 #DrugDev

Life science SEO works best when you treat it like a lab experiment. Test terminology, measure engagement, and refine based on data. Small changes in phrasing can shift who finds your content. Think like a scientist, market like one too: hubs.la/Q03VX4jt0 #SEO #LifeScience

People with IBD often face hidden psychosocial burdens: 85% feel misunderstood and 78% feel isolated. Shared decision-making and patient communities help, with 44% reporting improved mental and physical well-being. Read the full report: hubs.la/Q03VX1C20 #PatientEngagement

Phase 0 studies are gaining traction in radiopharma. They use imaging and microdoses to confirm your drug reaches its target in humans before you commit to Phase 1. When executed well, they're a strategic filter that saves time and money: hubs.la/Q03VX3q50 #ClinicalTrials

A Chinese drugmaker just became the world's top trial sponsor, but that's not the only shift. CNS trials jumped 14.7%, autoimmune rose 14.6%, and cardiovascular grew 15.6%. The clinical trial landscape is moving fast in 2025. Find out more: hubs.la/Q03VX45K0 #Pharma

The GLP-1 hype cycle shows what happens when marketing outruns science. A celebrity endorsement became a cultural moment, but the message blurred patient education and promotion. In life sciences, the molecule isn't the challenge; it's the message: hubs.la/Q03VX5rB0 #GLP1

Richard Pazdur is the FDA's new CDER director. The 26-year oncology chief reportedly turned down the role, but Commissioner Makary insisted. He's stepping in after George Tidmarsh resigned amid a conduct probe. Is this stability at last? hubs.la/Q03VX5pX0 #Oncology #FDA

Google judges life science content like a peer reviewer: it wants proof of credibility. Show experience, cite credible sources, feature expert authors, and keep content updated. When your digital presence reflects scientific rigor, visibility follows: hubs.la/Q03VX5QF0 #SEO

#Alzheimer's drugs are finally gaining traction. Doctors are getting comfortable with the protocols, new at-home injections reduce hospital visits, and modified dosing lowers brain bleed risks. The barriers were safety, infrastructure, and familiarity: hubs.la/Q03VX7nk0

Rising healthcare costs could reverse years of progress in clinical trial diversity. With premiums up 59% and trial costs hitting $100-$1K per visit, participation is dropping, especially in underrepresented communities. Read the insights hubs.la/Q03YSPzw0 #PatientDiversity

Your RWD vendor can tell you everything, except which patients used your product. Data partnerships with hospitals help overcome this. They track real performance and build brand-specific evidence that differentiates. Find out more: hubs.la/Q03YSNcF0 #RWD #LifeSci